Benjamin Click, MD: Biosimilars in IBD

Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses how biosimilars fit in the treatment paradigm for inflammatory bowel disease (IBD).

Transcript

Yes, so I think biosimilars have the opportunity to potentially change the biologic landscape. Biosimilars are just starting to come into routine clinical practice in the United States. They’ve been used for several more years in European and non-American countries, so a lot of the more long-term experience coming from the European colleagues is very encouraging.

We are starting to routinely use biosimilars, mostly for infliximab at this point in time, though we do hope to see a biosimilar for adalimumab hit the market in the next several years. So I think there’s a lot of potential cost savings opportunity when we think about healthcare costs in the United States and how we can potentially impact those as well.

Related Videos
Christine Baeder Smiling
Michael Kleinrock
Ian Henshaw
Ian Henshaw
Ryan Haumschild, PharmD
John Gabrielson
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumdschild, PharmD
banner for the ophthalmology linkedin live event sponsored by the samsung bioepis in partnership with the center for biosimilars
Ryan Haumschild, PharmD
Related Content
© 2023 MJH Life Sciences

All rights reserved.